Immunogenicity of measles-rubella vaccine administered under India's Universal Immunization Programme in the context of measles-rubella elimination goal: A longitudinal study
CONCLUSIONS: MR vaccine administered below one year of age under the UIP resulted in seroprotection against rubella and measles in a large majority of children. Furthermore, its second dose resulted in seroprotection of all children. The current MR vaccination strategy of two doses, out of which the first is to be given to infants below one year of age, appears robust and justifiable among Indian children.PMID:37102515 | DOI:10.4103/ijmr.IJMR_4113_20
Source: The Indian Journal of Medical Research - Category: Biomedical Science Authors: Santosh Kumar Verma Dheeraj Shah Aaradhana Singh Praveen Kumar Singh Shukla Das Piyush Gupta Source Type: research
More News: Biomedical Science | Children | India Health | Measles | Measles Vaccine | Research | Rubella | Rubella Vaccine | Study | Vaccines